Septocaine: Uses, Dosage & Side Effects

What Is Septocaine and What Is It Used For?

Septocaine is the trade name under which Septodont (a French pharmaceutical company specializing in dental anesthetics) markets the combination of articaine hydrochloride and epinephrine. Articaine was first synthesized in Germany in 1969 (originally under the name carticaine) and was introduced into European clinical practice in 1976. It was approved by the U.S. Food and Drug Administration (FDA) for dental use in 2000 as Septocaine, and has since become one of the most widely used dental local anesthetics in many countries. Large cross-sectional surveys indicate that in some European markets, articaine formulations now account for the majority of dental local anesthetic use.

Articaine belongs to the amide class of local anesthetics, which also includes lidocaine, mepivacaine, prilocaine, bupivacaine and ropivacaine. However, articaine is chemically distinct from other amides in two important ways. First, it contains a thiophene ring instead of a benzene ring in its aromatic portion; this heterocyclic ring increases the molecule's lipid solubility, which in turn improves its penetration through bone and soft tissue, particularly relevant in the dense cortical bone of the lower jaw. Second, articaine has an additional ester side-chain. This ester is rapidly hydrolyzed by non-specific plasma esterases, meaning that although articaine is classified as an amide, its metabolism more closely resembles that of ester-type local anesthetics such as procaine.

Pharmacologically, articaine produces local anesthesia by the same mechanism as other local anesthetics: it reversibly blocks voltage-gated sodium channels in the nerve cell membrane. When articaine binds to these channels, it prevents the rapid influx of sodium ions that normally generates an action potential, and nerve impulse propagation is interrupted. The differential nerve block that follows means that small, unmyelinated fibers carrying pain and temperature are blocked first, followed by fibers transmitting touch and pressure, and finally (and least completely) the large motor fibers. Clinically, this allows a tooth to be drilled, extracted or treated endodontically while the patient remains conscious, comfortable and pain-free.

The 1:200,000 epinephrine (adrenaline) concentration in Septocaine 40 mg/ml + 5 µg/ml adds an essential second pharmacological effect. Epinephrine is a sympathomimetic agent that, at low doses applied locally, binds predominantly to alpha-1 adrenergic receptors on the smooth muscle of small blood vessels. This causes vasoconstriction, reducing local blood flow at the injection site. The result is that articaine is absorbed more slowly into the systemic circulation, which: (1) extends the duration of anesthesia at the site, (2) decreases the peak plasma concentration of articaine and thereby reduces the risk of systemic toxicity, (3) permits a lower total anesthetic dose to achieve the same clinical effect, and (4) reduces bleeding at the surgical site, improving visibility and facilitating surgery. The 1:200,000 dilution (5 µg/ml) is the lower of the two epinephrine concentrations commonly used with articaine; the 1:100,000 dilution (10 µg/ml) provides slightly more vasoconstriction but is generally reserved for procedures requiring more pronounced hemostasis.

Septocaine is indicated for infiltration anesthesia and nerve block anesthesia in routine dental and oral surgical procedures. Typical clinical applications include:

• Routine restorative dentistry: Anesthesia for dental caries (cavity) removal, placement of fillings, crown preparation, and other routine tooth-conserving procedures. Buccal infiltration with articaine frequently provides adequate pulpal anesthesia for mandibular as well as maxillary teeth, a distinctive clinical advantage compared with lidocaine.
• Simple and surgical tooth extraction: Removal of erupted teeth, retained roots and impacted teeth, including third molar (wisdom tooth) surgery. The improved hemostasis from epinephrine supports surgical access and postoperative clot stability.
• Endodontic therapy: Root canal treatment of inflamed or infected pulps. Achieving profound pulpal anesthesia in teeth with irreversible pulpitis can be clinically challenging, and articaine has been reported in meta-analyses to produce higher rates of successful anesthesia than lidocaine in these cases when used for supplemental infiltration following an inferior alveolar nerve block.
• Periodontal surgery: Scaling and root planing in deep periodontal pockets, flap surgery, crown-lengthening procedures and mucogingival surgery, where both anesthesia and local hemostasis are desired.
• Implant dentistry: Placement of dental implants, sinus lift procedures and bone grafting in patients without contraindications to amide anesthetics or to epinephrine.
• Pediatric dentistry (children aged 4 years and older): Routine dental work in suitably selected children, with dose adjustment strictly according to body weight. Articaine is not recommended in children under the age of 4 years because of limited safety data in that age group.

Pharmacokinetically, articaine is absorbed rapidly from the submucosal tissues of the oral cavity, with peak plasma concentrations typically reached within about 25 minutes of submucosal injection. Protein binding is approximately 60–80%, predominantly to alpha-1-acid glycoprotein. The volume of distribution is roughly 1.7 L/kg. The defining feature of articaine's pharmacokinetics is its biphasic elimination: approximately 90–95% of an absorbed dose is rapidly hydrolyzed in plasma and tissues by non-specific esterases to the pharmacologically inactive metabolite articainic acid (articaine acid). Only about 5–10% undergoes hepatic metabolism via the cytochrome P450 3A4 pathway. This dual pathway results in a short terminal elimination half-life of approximately 20–40 minutes, which is significantly shorter than that of lidocaine (90–120 minutes), mepivacaine (approximately 115 minutes) or bupivacaine (approximately 160 minutes). The short half-life means articaine is cleared quickly even in patients with mild to moderate hepatic impairment, and it reduces the risk of systemic accumulation when multiple cartridges must be used over the course of a lengthy procedure.

The epinephrine component is metabolized rapidly by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) at the injection site, in the liver and in other tissues. Most of the absorbed epinephrine is eliminated within minutes, but even this small systemic exposure can, in susceptible patients, contribute to transient increases in heart rate, blood pressure or anxiety symptoms.

What Should You Know Before Taking Septocaine?

Contraindications

Septocaine is contraindicated in the following situations:

• Hypersensitivity to amide local anesthetics: Known allergy to articaine, lidocaine, mepivacaine, prilocaine, bupivacaine, ropivacaine or other amide-type agents, or to any excipient in the formulation. True IgE-mediated allergy to amide anesthetics is extremely rare, but when confirmed, cross-reactivity among amide agents must be assumed.
• Hypersensitivity to sulfites: Septocaine contains sodium metabisulfite (or another sulfite) as an antioxidant to stabilize epinephrine. Patients with a known sulfite allergy, particularly severe asthmatics in whom sulfite exposure can trigger bronchospasm, should not receive Septocaine. In this group a sulfite-free alternative (for example, plain mepivacaine or articaine without epinephrine) is preferred.
• Hypersensitivity to epinephrine: Known hypersensitivity to epinephrine or other sympathomimetics.
• Severe, uncontrolled cardiovascular disease: Including recent myocardial infarction (within the past 3–6 months), unstable angina, severe uncontrolled arterial hypertension, severe uncontrolled arrhythmias, recent coronary artery bypass surgery (within 3 months), and severe uncontrolled heart failure, in whom even the small systemic epinephrine load could precipitate complications.
• Paroxysmal supraventricular tachycardia and high-risk arrhythmias: Because of the sympathomimetic effects of epinephrine.
• Pheochromocytoma: An adrenal tumor secreting catecholamines; additional epinephrine can trigger a hypertensive crisis.
• Narrow-angle glaucoma: Systemic absorption of epinephrine can increase intraocular pressure.
• Severe hyperthyroidism (thyrotoxicosis): Hyperthyroid patients are more sensitive to the cardiovascular and metabolic effects of epinephrine.
• Severe hepatic impairment: Although only a minor fraction of articaine is metabolized hepatically, severe hepatic dysfunction may still prolong clearance and reduce plasma esterase activity.
• Porphyria: Articaine may precipitate acute attacks in patients with known or latent porphyria.
• Intravenous administration: Septocaine must never be administered intravenously. Always aspirate before injection.
• Children under 4 years of age: Safety and efficacy of articaine have not been adequately established in this age group.

Warnings and Precautions

Before receiving Septocaine, inform your dentist or physician about the following conditions, as they may require dose adjustment, additional monitoring, or the use of an alternative local anesthetic:

• Cardiovascular disease: Controlled ischemic heart disease, well-treated hypertension, stable arrhythmias and treated heart failure are generally not absolute contraindications, but the lowest effective dose of articaine and epinephrine should be used. For most dental procedures, the small epinephrine load in a 1:200,000 formulation is well tolerated by stable cardiac patients, and avoiding vasoconstrictor entirely may actually increase cardiovascular risk by allowing greater systemic absorption of the anesthetic and more pain-related endogenous catecholamine release.
• Hypertension: Patients with controlled hypertension may generally receive Septocaine at a reduced dose with careful monitoring. In uncontrolled hypertension, dental treatment should be deferred until blood pressure is stabilized.
• Diabetes mellitus: Epinephrine may transiently raise blood glucose. Patients on oral hypoglycemic agents or insulin should be aware of possible short-term glycemic variation.
• Asthma, especially severe or sulfite-sensitive asthma: Because of the sulfite content, patients with severe asthma are at increased risk of bronchospasm. A sulfite-free alternative is preferable in this group.
• Epilepsy and seizure disorders: Articaine, like all local anesthetics, can lower the seizure threshold at high plasma levels. Dose limits must be strictly observed.
• Hepatic impairment: Because approximately 5–10% of articaine is cleared by the liver, severe hepatic impairment may prolong its systemic effects. Plasma esterase activity may also be reduced in cirrhosis.
• Renal impairment: Articainic acid (the inactive metabolite) is excreted renally. Caution is advised in patients with severe chronic kidney disease.
• Pseudocholinesterase deficiency: Because articaine metabolism depends on plasma esterases, patients with atypical pseudocholinesterase or severe enzyme deficiency may experience prolonged drug effect. These patients typically know about their condition because of previous prolonged neuromuscular blockade after succinylcholine. In severe cases, an alternative anesthetic is preferred.
• Methemoglobinemia risk factors: Articaine, like prilocaine and benzocaine, can in very high doses induce methemoglobinemia, a condition in which hemoglobin is oxidized and cannot transport oxygen effectively. Patients with congenital methemoglobin reductase deficiency, glucose-6-phosphate dehydrogenase (G6PD) deficiency, or those taking other oxidizing drugs are at higher risk.
• Elderly and debilitated patients: Reduced cardiovascular reserve, decreased plasma protein levels, and lower esterase activity all favor a conservative approach to dosing in the elderly.
• Injection site considerations: Highly vascular areas such as the oral mucosa can produce faster systemic absorption. Aspiration before injection and slow injection (at least 30 seconds per cartridge) are essential to minimize the risk of accidental intravascular administration.
• Risk of prolonged paresthesia: Injection of any local anesthetic near a nerve trunk (especially the inferior alveolar or lingual nerve during mandibular block) carries a small risk of persistent paresthesia. Some case-series data have suggested a slightly higher rate of paresthesia with 4% formulations (articaine, prilocaine) compared to 2% formulations; this remains an area of ongoing clinical investigation.

Pregnancy and Breastfeeding

Elective dental treatment is generally deferred until after delivery. However, when dental treatment is clinically necessary during pregnancy — for example, to treat acute dental infection — appropriate local anesthesia is preferable to untreated pain or infection, both of which carry risks to the pregnancy.

Articaine crosses the placenta, but its rapid plasma hydrolysis to inactive articainic acid limits fetal exposure compared with more slowly metabolized amides. Published clinical experience does not suggest teratogenic effects or increased risk of adverse pregnancy outcomes when articaine with epinephrine is used at appropriate doses for dental procedures. The second trimester is traditionally considered the most favorable window for non-emergency dental work. The lowest effective dose should always be used, and aspiration before injection is particularly important to reduce the risk of inadvertent intravascular administration, which could transiently affect uterine blood flow.

Articaine is excreted into breast milk in extremely small amounts, and its inactive metabolite is rapidly cleared. Following a standard dental anesthetic dose, the amount transferred to the nursing infant is considered clinically negligible, and breastfeeding may be continued. Some guidelines suggest waiting approximately 4–6 hours after injection before the next feed simply as a precaution, but this is not strictly evidence-based. Informing the dentist about breastfeeding allows individualized advice.

Children and Adolescents

Septocaine is not recommended in children under the age of 4 years due to limited safety and efficacy data in this age group. In children aged 4 years and older, articaine with epinephrine can be used effectively for dental procedures, but doses must be carefully calculated on the basis of body weight. Pediatric patients are particularly vulnerable to the consequences of dose miscalculation because they have lower total body water, smaller volumes of distribution, and may be at higher risk of soft-tissue injury (lip or cheek biting) due to the long duration of post-procedural soft-tissue numbness. Pediatric dentists routinely counsel parents to monitor children for at least several hours after dental anesthesia to prevent accidental self-injury.

How Does Septocaine Interact with Other Drugs?

Because Septocaine contains two pharmacologically active substances — articaine (an amide local anesthetic) and epinephrine (a sympathomimetic vasoconstrictor) — its overall interaction profile is broader than that of a plain local anesthetic. Most clinically relevant interactions involve the epinephrine component, because the dose of articaine delivered per cartridge is small and its rapid plasma hydrolysis limits the duration of systemic exposure.

Major Interactions

The following table summarizes the most clinically significant interactions that dentists and physicians consider before administering articaine with epinephrine:

Minor and Theoretical Interactions

A commonly encountered clinical question is whether patients taking non-selective beta-blockers (such as propranolol) should avoid epinephrine-containing dental local anesthetics altogether. Current consensus guidelines from dental and cardiovascular societies state that a single 1.7–1.8 ml cartridge of 1:200,000 epinephrine is generally well tolerated even in these patients, provided that aspiration is performed before injection and injection is slow. However, multiple cartridges delivered in quick succession can precipitate clinically significant hypertension. When in doubt, a conservative approach is to use the minimum effective dose, monitor blood pressure, and consider plain mepivacaine if high doses of vasoconstrictor-containing anesthetic would otherwise be needed.

What Is the Correct Dosage of Septocaine?

Septocaine is supplied as a ready-to-use sterile solution in single-use dental cartridges of either 1.7 ml or 1.8 ml. Each 1.7 ml cartridge therefore contains 68 mg of articaine hydrochloride and 8.5 µg of epinephrine. Each 1.8 ml cartridge contains 72 mg of articaine hydrochloride and 9 µg of epinephrine. The dose is always individualized, taking into account the surgical procedure, the injection technique, the vascularity of the tissue, the age and physical status of the patient, and the required depth and duration of anesthesia. The lowest dose that produces effective anesthesia should be used.

Adults

For healthy adults, the recommended maximum single-dose of articaine is 7 mg/kg body weight, up to an absolute maximum of 500 mg per appointment. Most routine dental procedures can be completed with between 1 and 3 cartridges. Typical dosing ranges by procedure type are shown below.

Children (4–16 years)

Articaine can be used in children aged 4 years and older. Dosing must be strictly individualized by weight. A usual dose is 0.5–5 mg/kg, not exceeding 7 mg/kg in a single visit. Many pediatric dentists use substantially less than the maximum for routine procedures. Children under the age of 4 years should receive an alternative agent, as the safety of articaine has not been established in this age group.

Elderly Patients

Elderly patients may have reduced hepatic blood flow, reduced esterase activity, reduced plasma protein levels, and reduced cardiovascular reserve. These changes do not usually require a major dose reduction for routine single-cartridge injections, but the lowest effective dose should be used, particularly in patients with cardiovascular disease, and total doses approaching the upper limit should be avoided.

Patients with Cardiovascular or Hepatic Comorbidity

In patients with well-controlled cardiovascular disease, a single-cartridge administration of Septocaine 1:200,000 is generally considered safe. For patients with moderate hepatic impairment, doses should be reduced and slow injection technique used. In severe hepatic impairment, an alternative anesthetic may be preferred.

Missed Dose

Because Septocaine is administered by a clinician at the time of a procedure rather than taken routinely at home, the concept of a “missed dose” does not apply in the traditional sense. If additional anesthesia is needed during a procedure — for example, if the initial injection is insufficient or the procedure is longer than anticipated — the clinician will administer further Septocaine only if the cumulative dose remains below the maximum safe limit and provided aspiration is performed before each re-injection.

Overdose

Overdose may occur through inadvertent intravascular injection, excessive total dose, rapid absorption from highly vascular tissue, or impaired metabolism in susceptible patients. The signs and symptoms of systemic articaine toxicity are those of local anesthetic systemic toxicity (LAST) and typically evolve in a predictable sequence:

• Early CNS excitatory signs: Perioral tingling, metallic taste, tinnitus, lightheadedness, visual disturbances, anxiety, restlessness and muscle twitching.
• Progressive CNS depression: Slurred speech, drowsiness, loss of consciousness, seizures, respiratory depression and respiratory arrest.
• Cardiovascular toxicity: Hypotension, bradycardia, conduction disturbances (particularly at very high plasma levels), ventricular arrhythmias and cardiac arrest.
• Epinephrine-related effects: If intravascular injection occurs, the epinephrine component can cause transient severe hypertension, tachycardia or tachyarrhythmia.
• Methemoglobinemia: At very high doses, articaine can oxidize hemoglobin to methemoglobin, presenting as cyanosis unresponsive to oxygen. Treatment is intravenous methylene blue.

Management of suspected systemic toxicity includes immediate cessation of injection, airway management and oxygenation, intravenous access, benzodiazepines for seizures, advanced cardiovascular life support as needed, and consideration of intravenous lipid emulsion (20% Intralipid) for severe cardiovascular toxicity. Dental practices using local anesthetics are required in most jurisdictions to maintain emergency medications and trained staff to manage these rare events.

What Are the Side Effects of Septocaine?

Like all medicines, Septocaine can cause side effects, though not every patient will experience them. The majority of adverse effects are mild, self-limited, and attributable either to the expected pharmacological action of the drug (local numbness, soft-tissue anesthesia) or to transient systemic exposure to articaine and epinephrine. True allergy to amide local anesthetics is extremely rare.

Side effects can be broadly divided into local reactions at the injection site, systemic reactions from absorbed drug, and reactions related to excipients such as sulfites. The frequency categories below follow the standard regulatory classification used in European summaries of product characteristics.

Systemic toxicity from local anesthetics tends to progress in a dose-dependent, stepwise fashion, beginning with subtle central nervous system excitatory signs (metallic taste, tinnitus, perioral tingling, restlessness), moving through CNS depression (drowsiness, slurred speech, loss of consciousness and seizures) and finally to cardiovascular depression (hypotension, bradycardia, arrhythmias and cardiac arrest). Because articaine has a short elimination half-life, the window of systemic toxicity is generally brief if the drug has been administered extravascularly. However, rapid intravascular injection can produce very high transient plasma concentrations. This is why aspiration before injection and slow injection technique (at least 30 seconds per cartridge) are essential safety practices.

Persistent paresthesia — lasting weeks, months or in rare cases permanently — is a concerning but uncommon complication of any nerve-block injection. Published case series have associated paresthesia most often with inferior alveolar and lingual nerve blocks rather than with infiltration. Some retrospective data have suggested a slightly higher rate of paresthesia with 4% formulations (articaine and prilocaine) than with 2% lidocaine, while other studies have not confirmed this association. The absolute risk remains very low (roughly 1 in 27,000 to 1 in 800,000 injections in large series), but patients should be informed that nerve injury, although rare, is a recognized complication of mandibular block anesthesia with any local anesthetic.

True allergic reactions to articaine are exceedingly rare, because the amide bond at the aromatic end of the molecule does not generate para-aminobenzoic acid (PABA), the metabolite historically associated with ester-anesthetic allergy. Many reported “allergic reactions” to articaine-containing products are actually vasovagal episodes, panic reactions or responses to the sulfite preservative. When genuine amide-anesthetic allergy is suspected, formal allergy testing by an allergist (using skin prick and intradermal testing with preservative-free solutions) should be arranged before future procedures.

How Should You Store Septocaine?

Proper storage of Septocaine is essential to maintain the sterility, potency and physical integrity of the solution. Both components — articaine and epinephrine — can be affected by heat, light, and freezing, and epinephrine is particularly prone to oxidation. The sulfite antioxidant in the formulation helps to stabilize epinephrine but does not eliminate the need for careful storage conditions.

• Temperature: Store at a controlled room temperature not exceeding 25 °C (77 °F). Avoid storing near heating equipment, autoclaves, or in direct sunlight. Temperatures above 25 °C can accelerate degradation of epinephrine.
• Do not freeze: Freezing can damage the cartridge, cause the rubber stopper to separate, and may produce micro-fractures in the glass. If a cartridge has been accidentally frozen, it must be discarded.
• Light protection: Keep cartridges in the original outer packaging to protect from light. Light exposure accelerates oxidation of the epinephrine component, which may manifest as a pink or brown discoloration of the solution.
• Do not use if discolored: The solution should be clear and colorless. A pink, brown or cloudy solution indicates oxidative degradation and must not be used, even if the expiration date has not yet passed.
• Inspect before use: Before each injection, the dentist should visually inspect the cartridge for cracks, air bubbles larger than 2 mm, displacement of the rubber stopper, or discoloration. Any abnormality is a reason to discard the cartridge.
• Single-use only: Each cartridge is intended for administration to a single patient at a single visit. Any remaining solution in a used cartridge must be discarded in accordance with local clinical waste regulations.
• Expiration date: Do not use after the expiration date printed on the cartridge and carton. The expiration date refers to the last day of the printed month.
• Keep out of reach of children and unauthorized persons: Store in a dedicated, secure medication cabinet in the dental facility, accessible only to clinical staff.

Within dental practices, inventory of Septocaine and other local anesthetic cartridges should follow the first-in, first-out (FIFO) principle, so that cartridges with the earliest expiration dates are used first. Routine stock checks help ensure that expired or damaged units are removed from the clinical supply. In larger facilities, temperature monitoring of storage areas (with minimum/maximum thermometers) is an important component of quality assurance.

What Does Septocaine Contain?

Understanding the composition of Septocaine is important for both clinicians and patients, particularly those with known allergies or sensitivities to specific pharmaceutical excipients. Below is a detailed breakdown of a typical articaine 40 mg/ml + epinephrine 5 µg/ml formulation (the exact excipient list may vary slightly between regulatory regions and manufacturers, so patients with known allergies should check the current package insert).

Active Ingredients

Septocaine contains two active substances:

• Articaine hydrochloride: the amide-type local anesthetic. Each millilitre of solution contains 40 mg, corresponding to a 4% (w/v) concentration. Chemical formula C₁₃H₂₀N₂O₃S · HCl; molecular weight approximately 320.8 g/mol. A thiophene ring in place of the traditional benzene ring enhances lipid solubility and tissue diffusion.
• Epinephrine (adrenaline): the sympathomimetic vasoconstrictor, typically incorporated as epinephrine bitartrate to improve stability. Each millilitre contains 5 µg of epinephrine base, equivalent to a 1:200,000 dilution. Chemical formula (free base) C₉H₁₃NO₃; molecular weight 183.2 g/mol.

Inactive Ingredients (Excipients)

A consequence of stabilizing epinephrine at a low pH (typically around 3.5–5.0) is that articaine is present predominantly in its protonated, water-soluble form in the cartridge. Once injected into tissue at physiological pH, it rapidly equilibrates with its uncharged base form, which penetrates nerve membranes to exert its anesthetic effect. This pH characteristic also contributes to the transient burning or stinging sensation that some patients report during injection; slow injection and warming the cartridge to body temperature can reduce this.

Appearance and Pack Sizes

Septocaine is supplied as a clear, colorless to very pale straw-colored sterile solution in single-use glass dental cartridges of 1.7 ml or 1.8 ml. Cartridges are typically packaged in boxes of 50 or 100. Not all pack sizes may be available in every country. The cartridge is designed for use with a standard aspirating dental syringe.

Marketing Authorization Holder and Manufacturer

Septocaine is manufactured and marketed by Septodont, a French pharmaceutical company with its headquarters near Paris. Septodont is one of the world's leading manufacturers of dental local anesthetics and dental pharmaceutical products, with distribution in more than 150 countries. The company operates in compliance with European and U.S. Good Manufacturing Practice (GMP) standards. In different regulatory markets, articaine + epinephrine formulations are also sold by various manufacturers under alternative brand names such as Ubistesin, Septanest, Astracaine, Orabloc and others. These generic and branded products have the same core active ingredient composition and, when correctly manufactured, are therapeutically equivalent.